Popular on eTradeWire
- New Novel Tells a Whale of a Traveler's Tale (Minus the Whale) - 169
- Arabella Wellness Center Launches Campaign to Expand Access to Women's Wellness Services Across North Texas - 155
- Queer Horror Poetry Collection Monsters in the Closet Now Available in Paperback - 155
- Can Your Inner Child Come Out and Play - 136
- Nieves Ministries Leads with Faith to Fortify Safety, Education, and Puerto Rican Culture in Colorado - 133
- Max Tucci dishes out hundreds of Chicken Parm Sandwiches to Bilt members on Rent Day, June 1st, 2025 - 123
- ECoffeeFinder.com's Father's Day Mugs: Sleep Deprived, Dad Jokes & Adventure Dad - 121
- Carnegie Hall Hosts Theatrical Concert: El Dorado – A Musical Portrait of Edgar Allan Poe - 119
- RockNTix Announces Strategic Partnership with Microsoft to Power Next-Gen Event Ticketing Platform - 119
- San Francisco Hometown Star Terri J. Vaughn Hits Streaming Highs in Tyler Perry Studios "She the People" on Netflix - 117
Similar on eTradeWire
- Vision Share to Distribute KeraNatural® & halo® in Select Global Markets
- ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
- Introducing GANCloud — The Future of Memory Starts Here
- ReproTech LLC Invests in Matcher Technologies Ltd
- $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
- Ace Therapeutics Launches Validated Disease Model Aiming to Elevate Gastroenterology Research to New
- ARCH Dental + Aesthetics Unveils New Website for Enhanced Patient Experience
- Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform
- CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- Phoenix Implant Clinic Introduces Upfront Cost Page to Strengthen Patient Trust
Quantoom Biosciences & Tiamat Sciences Announce Strategic Partnership to Revolutionize mRNA Product
eTradeWire News/10771118
DURHAM, N.C. - eTradeWire -- Quantoom Biosciences and Tiamat Sciences Announce Strategic Partnership to Revolutionize mRNA Production
Quantoom Biosciences S.A. ("Quantoom"), part of Univercells S.A., focused on mRNA production technologies for vaccines and therapeutics, and Tiamat Sciences, a plant-based platform and product life sciences company, are thrilled to announce a groundbreaking partnership aimed at bringing mRNA technology to a broader audience.
Under this partnership, Tiamat Sciences will work on feasibility evaluation, development and supply of a series of key enzymes in support of the innovative platform production processes developed at Quantoom Biosciences. This collaboration is set to revolutionize the way mRNA is produced, making it more efficient, cost-effective, and environmentally sustainable.
A New Era in mRNA Production
Quantoom Biosciences and Tiamat Sciences are at the forefront of innovation in mRNA technology. By leveraging Tiamat's plant-based expression systems, the partnership aims to significantly enhance innovation within mRNA production processes, which is crucial for the development of vaccines and therapeutics.
More on eTradeWire News
Statements from Leadership
Quantoom Biosciences CEO, Jose Castillo, stated, "We are thrilled to engage in this collaboration with Tiamat Sciences. By combining our expertise in mRNA manufacturing with Tiamat Sciences' innovative approach to enzyme development, we believe we can significantly enhance our ability to deliver groundbreaking solutions in the mRNA field. This strategic partnership represents a tremendous opportunity to improve access to healthcare and further increase the affordability of new treatments ."
Tiamat Sciences CEO, France-Emmanuelle Adil, added, "We are proud to join forces with Quantoom Biosciences. This partnership not only underscores the scientific milestones we have achieved but also highlights the immense potential of plant-based expression systems in transforming the future of pharmaceutical production."
Revolutionizing Pharmaceutical Production
The collaboration between Quantoom and Tiamat is poised to set new standards in the pharmaceutical industry. By utilizing plant-based expression systems for essential reagents, the partnership demonstrates a commitment to sustainability and innovation, ensuring that the future of protein production is both environmentally friendly and highly efficient.
More on eTradeWire News
About Quantoom Biosciences
Quantoom Biosciences is reinventing mRNA production by developing an RNA platform that includes RNA manufacturing and formulation. Their RNA manufacturing technology, Ntensify™, encompasses process, equipments, mixes of reagents, and disposables designed for seamless integration across various scales, making it an ideal choice from research to to large-scale manufacturing. Ncapsulate™ is a fully integrated and automated system tailored for GMP mRNA formulation and designed to meet the rigorous standards of both clinical and commercial manufacturing. Quantoom Biosciences's facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences group with the mission of making biologics accessible to all.
https://quantoom.com/
About Tiamat Sciences
Tiamat Sciences is a pioneering life sciences company that uses plant-based platforms to produce reagents. Their innovative approach is transforming the way proteins are produced, emphasizing efficiency, cost-effectiveness, and environmental sustainability. Tiamat Sciences has recently made notable advancements by expressing T7 polymerase, a crucial enzyme for mRNA vaccine synthesis.
https://www.tiamat-sciences.com/
Quantoom Biosciences S.A. ("Quantoom"), part of Univercells S.A., focused on mRNA production technologies for vaccines and therapeutics, and Tiamat Sciences, a plant-based platform and product life sciences company, are thrilled to announce a groundbreaking partnership aimed at bringing mRNA technology to a broader audience.
Under this partnership, Tiamat Sciences will work on feasibility evaluation, development and supply of a series of key enzymes in support of the innovative platform production processes developed at Quantoom Biosciences. This collaboration is set to revolutionize the way mRNA is produced, making it more efficient, cost-effective, and environmentally sustainable.
A New Era in mRNA Production
Quantoom Biosciences and Tiamat Sciences are at the forefront of innovation in mRNA technology. By leveraging Tiamat's plant-based expression systems, the partnership aims to significantly enhance innovation within mRNA production processes, which is crucial for the development of vaccines and therapeutics.
More on eTradeWire News
- F&M Bank Supports WeBuild Concord's Vision for Attainable Housing
- Umbrella Partners with Synthesis to Deliver Scalable FinOps Value Across Multi-Cloud Environments
- Navigator NIL/Announces Signing of Dynamic Georgia Linebacker Kiersten Lee
- Court Denies Santa Barbara County's Motion To Dismiss Over Recycling Facility Dispute
- Boulder SEO Marketing Helps Seattle Cat Breeder Fill Waitlist and Boost Traffic by 178%
Statements from Leadership
Quantoom Biosciences CEO, Jose Castillo, stated, "We are thrilled to engage in this collaboration with Tiamat Sciences. By combining our expertise in mRNA manufacturing with Tiamat Sciences' innovative approach to enzyme development, we believe we can significantly enhance our ability to deliver groundbreaking solutions in the mRNA field. This strategic partnership represents a tremendous opportunity to improve access to healthcare and further increase the affordability of new treatments ."
Tiamat Sciences CEO, France-Emmanuelle Adil, added, "We are proud to join forces with Quantoom Biosciences. This partnership not only underscores the scientific milestones we have achieved but also highlights the immense potential of plant-based expression systems in transforming the future of pharmaceutical production."
Revolutionizing Pharmaceutical Production
The collaboration between Quantoom and Tiamat is poised to set new standards in the pharmaceutical industry. By utilizing plant-based expression systems for essential reagents, the partnership demonstrates a commitment to sustainability and innovation, ensuring that the future of protein production is both environmentally friendly and highly efficient.
More on eTradeWire News
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
- Bokka Group Elevates Home Builder Success with Specialized Marketing Services
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- CHRP 2.0 Officially Launches — Music Just Became Your Mental Edge
- MakeDongle Provides USB Dongle Licensing for Mac, Windows or Linux
About Quantoom Biosciences
Quantoom Biosciences is reinventing mRNA production by developing an RNA platform that includes RNA manufacturing and formulation. Their RNA manufacturing technology, Ntensify™, encompasses process, equipments, mixes of reagents, and disposables designed for seamless integration across various scales, making it an ideal choice from research to to large-scale manufacturing. Ncapsulate™ is a fully integrated and automated system tailored for GMP mRNA formulation and designed to meet the rigorous standards of both clinical and commercial manufacturing. Quantoom Biosciences's facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences group with the mission of making biologics accessible to all.
https://quantoom.com/
About Tiamat Sciences
Tiamat Sciences is a pioneering life sciences company that uses plant-based platforms to produce reagents. Their innovative approach is transforming the way proteins are produced, emphasizing efficiency, cost-effectiveness, and environmental sustainability. Tiamat Sciences has recently made notable advancements by expressing T7 polymerase, a crucial enzyme for mRNA vaccine synthesis.
https://www.tiamat-sciences.com/
Source: Tiamat Sciences Corporation
Filed Under: Biotech
0 Comments
Latest on eTradeWire News
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
- Loyal Locker® Launches Beta to Empower Black-Owned Businesses with Next-Gen Loyalty Platform
- Mike Diamond Plumbing, HVAC & Electrical Offers Free House Call on Plumbing Repairs in Anaheim, CA
- Ray Buffer Menaces as "Frank Beatty" in Sci-Fi Western The Lord of All Future Space
- ICON CEO J Bradley Hall to Showcase Innovative AU Backed Digital Currency AUREALS™ at July BRICS Event in Rio
- King Virtual Services Takes Out Support Service Business of the Year 2025 at National Beam Awards
- Couture By Elesia Launches the Radiant Hiya Sunshine Line Featuring Meica Miller
- Fibrecross Unveils Next-Generation 800G Optical Transceiver
- MoonTown Records & Publishing Presents "Gonna Stay Friends" by Pariss El
- WELLFIT Unveils New Incline Walking Pad Treadmill for Smarter Home and Office Fitness
- How Life's Turning Points Inspired a New Short Story Collection
- New DAO-Powered System Promises to Revolutionize Micropayments — Visa Endorses
- GMO Miner: Creating a simple, efficient and reliable new cloud mining experience
- Grobecker Launches No-Repayment Down Payment Assistance Program for California
- TIA LYNN — A shining star blazing her own trail in the music universe
- DOT Miners launches a new cloud mining platform: low threshold, high transparency, and helps promote the inclusion of global digital assets
- Brothers of Kelly Park Awarded NOF-ARPA Grant for 2025 B.O.K. Free Summer Basketball Camp
- America's Finest Moving & Storage Completes Major Merger, Expanding Services Across The Country
- Auraya Announces Partnership with Five9 to offer a seamless and secure voice biometric verification
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases